Select Publications

    2016
    Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF. Density of immunogenic antigens does not explain the presence or absence of the T cell-inflamed tumor micro-environment in melanoma. Proc Natl Acad Sci USA 113:E7759-68, 2016.  PMC5137753

    Luke JJ, Zha Y, Matijevich K, Gajewski TF.  Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. J Immunother Cancer 4:35, 2016.  PMC4915048

    Artz AS, Logan B, Zhu X,  Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica 101:1426-33, 2016.

    2015
    Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic b-catenin signaling prevents anti-tumor immunity. Nature 523:231-5, 2015.

    Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40, 2015. PMC4304973

    O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamics biomarkers in a trial of sequentially administered Sunitinib and Cilengitide. Clin Cancer Res 21:5092-9, 2015.  PMC4677671

    Maitland ML, Xu CF, Cheng YC, Kistner-Griffin E, Ryan KA, Karrison TG, Das S, Torgerson D, Gamazon ER, Thomeas V, Levine MR, Wilson PA, Bing N, Liu Y, Cardon LR, Pandite LN, O'Connell JR, Cox NJ, Mitchell BD, Ratain MJ, Shuldiner AR. Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res 21:365-72, 2015.  PMC4323272

    Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma:  SWOG 0933. Cancer 121:432-40, 2015.  PMC4304973

    2014
    Thomeas V, Chow S, Gutierrez JO, Karovic S, Wroblewski K, Kistner-Griffin E, Karrison TG Maitland ML. Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors. J Clin Pharmacol 54:682-7, 2014.  PMC3600382

    2013
    Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 5:200ra116, 2013.  PMC4136707

    Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol 55:283-91, 2013.  PMC3646929

    Geynisman DM, Zha Y, Junnavakkma R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrision TG, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer 1:8, 2013.  PMC4019890

    Gangadhar TC, Clark JI, Karrison TG, Gajewski TF. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs 31:769-73, 2013.  PMC3600382

    2012
    Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G Bucher C, Blaskovich MA, Sebti SM, Haluska F; Cancer and Leukemia Group B. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB500104). J Transl Med 10:246, 2012.  PMC3543225

    Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res 18:4785-93, 2012.  PMC4410974